Balstilimab
- Generic Name
- Balstilimab
- Brand Names
- -
- Drug Type
- Biotech
- Chemical Formula
- -
- CAS Number
- 2148321-77-9
- Unique Ingredient Identifier
- 1Q2QT5M7EO
- Associated Conditions
- -
- Associated Therapies
- -
Botensilimab, Balstilimab and Regorafenib or Botensilimab and Balstilimab for the Treatment of Advanced or Metastatic Microsatellite Stable Colorectal Cancer
- Conditions
- Stage IV Colorectal Cancer AJCC v8Advanced Colon AdenocarcinomaStage IV Colon Cancer AJCC v8Advanced Colorectal AdenocarcinomaMetastatic Colorectal AdenocarcinomaAdvanced Rectal AdenocarcinomaMetastatic Colon AdenocarcinomaStage III Colon Cancer AJCC v8Stage IV Rectal Cancer AJCC v8Metastatic Rectal Adenocarcinoma
- Interventions
- First Posted Date
- 2024-08-28
- Last Posted Date
- 2024-11-21
- Lead Sponsor
- City of Hope Medical Center
- Target Recruit Count
- 84
- Registration Number
- NCT06575725
- Locations
- 🇺🇸
City of Hope Medical Center, Duarte, California, United States
KRAS-Targeted Vaccine Combined With Balstilimab and Botensilimab for Patients With Stage IV MMR-p Colorectal Cancer and Pancreatic Ductal Cancer
- Conditions
- Interventions
- First Posted Date
- 2024-05-13
- Last Posted Date
- 2024-11-15
- Target Recruit Count
- 50
- Registration Number
- NCT06411691
- Locations
- 🇺🇸
Sidney Kimmel Comprehensive Cancer Center, Baltimore, Maryland, United States
Combination of Immune Checkpoint in Locally Advanced or Metastatic MSI/dMMR Esogastric Adenocarcinomas
- Conditions
- Interventions
- First Posted Date
- 2024-04-03
- Last Posted Date
- 2024-08-23
- Lead Sponsor
- Centre Leon Berard
- Target Recruit Count
- 124
- Registration Number
- NCT06346197
- Locations
- 🇫🇷
Centre Léon Bérard, Lyon, France
Platform Study of Immunotherapy Combinations in Colorectal Cancer Liver Metastases
- Conditions
- Interventions
- First Posted Date
- 2024-03-08
- Last Posted Date
- 2024-04-12
- Lead Sponsor
- Weill Medical College of Cornell University
- Target Recruit Count
- 24
- Registration Number
- NCT06300463
- Locations
- 🇺🇸
Weill Cornell Medicine/NewYork-Presbyterian Hospital, New York, New York, United States
Pan-tumor Neoadjuvant Basket Study of Immune Check-point Inhibition and Novel Immuno-oncology Combinations
- Conditions
- Interventions
- First Posted Date
- 2024-02-26
- Last Posted Date
- 2024-02-26
- Lead Sponsor
- The Netherlands Cancer Institute
- Target Recruit Count
- 92
- Registration Number
- NCT06279130
- Locations
- 🇳🇱
The Netherlands Cancer Institute, Amsterdam, Noord-Holland, Netherlands
Botensilimab and Balstilimab Optimization in Colorectal Cancer
- Conditions
- Interventions
- First Posted Date
- 2024-02-20
- Last Posted Date
- 2024-11-20
- Lead Sponsor
- Nicholas DeVito, MD
- Target Recruit Count
- 15
- Registration Number
- NCT06268015
- Locations
- 🇺🇸
Duke University, Durham, North Carolina, United States
A Study of agenT-797 in Combination With Botensilimab, Balstilimab, Ramucirumab, and Paclitaxel for People With Esophageal, Gastric, or Gastro-esophageal Junction Cancer
- Conditions
- Unresectable Esophageal AdenocarcinomaUnresectable Gastric CarcinomaUnresectable Gastric AdenocarcinomaUnresectable Gastroesophageal Junction AdenocarcinomaMetastatic Esophageal CancerMetastatic Gastric CarcinomaMetastatic Esophageal CarcinomaAdvanced Unresectable Gastric AdenocarcinomaMetastatic Esophageal AdenocarcinomaMetastatic Gastric Adenocarcinoma
- Interventions
- First Posted Date
- 2024-02-09
- Last Posted Date
- 2024-11-05
- Lead Sponsor
- Memorial Sloan Kettering Cancer Center
- Target Recruit Count
- 37
- Registration Number
- NCT06251973
- Locations
- 🇺🇸
Memorial Sloan Kettering Suffolk-Commack (Limited protocol activities), Commack, New York, United States
🇺🇸Memorial Sloan Kettering Westchester (Limited Protocol Activities), Harrison, New York, United States
🇺🇸Memorial Sloan Kettering Cancer Center (All Protocol Activities), New York, New York, United States
The Seven Trial: Exploiting the Unfolded Protein Response
- Conditions
- Interventions
- First Posted Date
- 2023-10-11
- Last Posted Date
- 2023-10-11
- Lead Sponsor
- HonorHealth Research Institute
- Target Recruit Count
- 12
- Registration Number
- NCT06076837
- Locations
- 🇺🇸
Clinical Trials Nurse Navigator, Scottsdale, Arizona, United States
Study of OBT076 Associated or Not in Patients with Recurrent or Metastatic Adenoid Cystic Carcinoma of the Head and Neck
- Conditions
- Interventions
- First Posted Date
- 2023-07-05
- Last Posted Date
- 2024-11-27
- Lead Sponsor
- Groupe Oncologie Radiotherapie Tete et Cou
- Target Recruit Count
- 19
- Registration Number
- NCT05930951
- Locations
- 🇫🇷
Hôpital Saint-André (Chu de Bordeaux), Bordeaux, France
Advanced Renal Cell Cancer Combination ImmunoThErapy Clinical Trial
- Conditions
- Interventions
- First Posted Date
- 2023-07-03
- Last Posted Date
- 2024-10-23
- Lead Sponsor
- Michael B. Atkins, MD
- Target Recruit Count
- 120
- Registration Number
- NCT05928806
- Locations
- 🇺🇸
Winship Cancer Institute of Emory University, Atlanta, Georgia, United States
🇺🇸University of California San Diego, La Jolla, California, United States
🇺🇸Yale University, Yale Cancer Center, New Haven, Connecticut, United States
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.